Dr. med. Thomas Ruhstaller
A Phase III Trial Evaluating the Role of Exemestane Plus GnRH Analogue as Adjuvant Therapy for Premenopausal Women with Endocrine Responsive Breast Cancer
Jun 1, 2005Das antihormonelle medikamentöse Standardmedikament ist Tamoxifen. Exemestane ist ein Medikament das bei fortgeschrittenem Brustkrebsleiden bei postmenopausalen Patientinnen angewendet wird. Die Verabreichung dieses Medikaments nach operiertem Brustk...
Clinical Studies - Jun 1, 2005 - Sep 30, 2015
Completed
Project leader: Ruhstaller Thomas
Members: Baumann Michael
Maintenance Chemotherapy in Hormone Non-Responsive Breast Cancer
Feb 1, 2001Angiogenesis, the process leading to the formation of new blood vessels, plays a central role in tumor progression of solid neoplasia. The switch from the avascular to the vascular phase is generally accompanied by rapid primary tumor growth and loca...
Clinical Studies - Feb 1, 2001 - Feb 1, 2015
Automatically Closed
Project leader: Ruhstaller Thomas
Members: Baumann Michael, Vogel Esther
Randomized phase III trial of Herceptin™ followed by Taxol plus Herceptin™ versus the combination of Herceptin™ and Taxol as palliative chemotherapy in patients with HER2-overexpressing advanced breast cancer
Nov 1, 1999To compare efficacy, toxicity and quality of life of the sequential administration of Her alone followed, at PD, by the combination with weekly Tax (Arm A) vs. the upfront combination of both drugs (Arm B) in patients with ABC.
Clinical Studies - Nov 1, 1999 - Nov 1, 2015
Automatically Closed
Project leader: Ruhstaller Thomas
Members: Baumann Michael